Wound Mgmt Tech (WNDM) 0.0995 $WNDM
Wound Management Technologies Receives Investment; Fully Pays Notes to Brookhaven Medical, Inc.; Mr. S. Oden Howell, Jr. Appointed to the Board of Directors
ACCESSWIRE - Thu Jun 18, 7:30AM CDT
ADDISON, TX / ACCESSWIRE / June 18, 2015 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that it has fully paid short term loans due to Brookhaven Medical Inc. This was made possible by investments from existing shareholders.
Wound Management Technologies Reports Amending and Termination of Its Shipping and Consulting Agreement with WellDyne Health
ACCESSWIRE - Thu Jun 11, 8:00AM CDT
ADDISON, TX / ACCESSWIRE / June 11, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced amending and terminating of its Shipping and Consulting Agreement dated September 19, 2013 with WellDyne Health in order to focus on its strategic shift to focus on sales internally.
Wound Management Technologies Reports Record Preliminary Financial Results for the First Quarter of 2015 and Enhanced Sales Team
ACCESSWIRE - Wed Apr 22, 9:12AM CDT
ADDISON, TX / ACCESSWIRE / April 22, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced record preliminary financial and operating results for the first quarter of 2015 and additions to its sales management team.
Wound Management Technologies, Inc. Schedules First Quarter 2015 Earnings Call for Wednesday, April 22, 2015
ACCESSWIRE - Mon Apr 20, 3:30PM CDT
ADDISON, TX / ACCESSWIRE / April 20, 2015 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced it will conduct a quarterly earnings call on Wednesday, April 22, 2015 at 3:00 p.m. CST. Robert Lutz, Jr., CEO, will discuss first quarter 2015 results and provide and update on recent activities. A question and answer session will follow the presentation. Shareholders, analysts and other interested parties may join the call by dialing 1-712-775-7031 passcode 604070847# shortly before 3:00 p.m. CST.
Wound Management Technologies Reports Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014
ACCESSWIRE - Thu Apr 09, 8:00AM CDT
ADDISON, TX / ACCESSWIRE / April 9, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced its financial and operating results for the fourth quarter and full year ended December 31, 2014.
Wound Management Technologies Exhibits at the American Academy of Orthopaedic Surgeons 2015 Annual Meeting
ACCESSWIRE - Wed Mar 18, 7:30AM CDT
ADDISON, TX / ACCESSWIRE / March 18, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM) ("Company"
, an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that its subsidiary, Wound Care Innovations ("WCI", will be an exhibitor at the American Academy of Orthopaedic Surgeons ("AAOS" Annual Meeting on March 24-28, to be held at the Venetian/Sands Expo in Las Vegas, Nevada. Wound Care Innovations will be located at booth #6729.
Wound Management Technologies Expands Internationally with Inaugural Order from Mexico
ACCESSWIRE - Mon Mar 16, 7:30AM CDT
ADDISON, TX / ACCESSWIRE / March 16, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM) ("Company", an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that Wound Care Innovations ("WCI", a subsidiary of the Company, received its inaugural order from Mexico, where WCI is registered and signed a distribution agreement with VISECA Desarrollo Inmobiliario SA de CA ("VISECA", a healthcare distributor in Mexico. CellerateRX(R) received COFEPRIS approval from the Mexico Ministry of Health.
Wound Management Technologies Reports Preliminary Financial Results For the Fourth Quarter and Year Ended December 31, 2014
ACCESSWIRE - Thu Jan 29, 7:31AM CST
ADDISON, TX / ACCESSWIRE / January 29, 2015 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced preliminary financial and operating results for the fourth quarter and year ended December 31, 2014.
Wound Management Technologies Appoints John Siedhoff to its Board of Directors
ACCESSWIRE - Tue Jan 13, 7:31AM CST
ADDISON, TX / ACCESSWIRE / January 13, 2015 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), announces that the Company has appointed John Siedhoff to its Board of Directors.
Wound Management Technologies Reports Financial Results for the Third Quarter Ended September 30, 2014
ACCESSWIRE - Thu Nov 13, 7:35AM CST
Addison, TX / ACCESSWIRE / November 13, 2014 / Wound Management Technologies, Inc. (OTC QB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced its financial and operating results for the three month period ended September 30, 2014.
Wound Management Technologies Appoints Ronald Goode and Jeffrey Lewis to the Board of Directors
Marketwired - Tue Oct 21, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), announces that the Company appointed Ronald Goode and Jeffrey Lewis to the Board of Directors.
Wound Management Technologies' CellerateRX(R) Featured in Clinical Research Session at the Symposium of Advanced Wound Care (SAWC) in Las Vegas, NV
Marketwired - Thu Oct 16, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that the product will be featured in an abstract accepted to the clinical research session at the Symposium of Advanced Wound Care (SAWC), which is being held at the Caesars Palace in Las Vegas, NV on October 16th - 18th, 2014.
Markets for Advanced Wound Management Technologies
PR Newswire - Tue Oct 14, 3:38PM CDT
This BCC Research report provides an overview of advanced wound care products, detailed market analyses and discussions of competitive environments. The study includes information about significant products, players, issues and trends and other information affecting the wound care industry.
Wound Management Technologies Appoints Dr. Blaine Farless as Medical Director of the Resorbable Orthopedic Products Subsidiary
Marketwired - Tue Oct 14, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that the Company appointed Dr. Blaine Farless as Medical Director of the Resorbable Orthopedic Products subsidiary (ROP).
Wound Management Technologies Launches Free Investor Relations App
Marketwire Canada - Tue Sep 16, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that the Company released an investor relations app for the iPhone, iPad and Android mobile devices.
Wound Management Technologies to Present at the Aegis Healthcare and Technology Conference in Las Vegas
Marketwire - Wed Sep 03, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patented-protected and FDA-cleared collagen product, CellerateRX(R), today announced that the Company's Chief Executive Officer, Robert Lutz, Jr., is scheduled to present at the Aegis Healthcare and Technology Conference on Friday, September 12, 2014 at 8:30AM PT at the Encore at the Wynn Hotel in Las Vegas, Nevada.
Wound Management Technologies Announces Its 2014 Annual Meeting of Shareholders
Marketwire - Tue Aug 26, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patented-protected and FDA-cleared collagen product, CellerateRX(R), announced that its 2014 Annual Meeting of Shareholders will be held at the Company's corporate offices located at 16633 Dallas Parkway, Suite 250 in Addison, TX on September 3, 2014 at 10AM CST.
Wound Management Technologies Launches Risk-Sharing Program to Reimburse Hospitals for Certain SSI Costs to Highlight Effectiveness of CellerateRX(r) Surgical
ACCESSWIRE - Tue Aug 19, 7:31AM CDT
Addison, TEXAS / ACCESSWIRE / August 19, 2014 / Wound Management Technologies, Inc. (OTC QB: WNDM), an emerging commercial stage company with its primary product, a patented-protected and FDA-cleared collagen product, CellerateRX(r), today announced that its Wound Care Innovations subsidiary has launched the CellerateRX(r) Surgical Assurance Program, a risk-sharing program to help hospitals and surgical centers lower the uncompensated care costs associated with readmissions due to surgical site infections (SSIs).
Wound Management Technologies Reports Financial Results for the Second Quarter Ended June 30, 2014
ACCESSWIRE - Thu Aug 14, 3:06PM CDT
Addison, TX / ACCESSWIRE / August 14, 2014 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patented-protected and FDA-cleared collagen product, CellerateRX(r), today announced its financial and operating results for the three month period ended on June 30, 2014.
Wound Management Technologies Receives Investment; Fully Pays Notes to Brookhaven Medical, Inc.; Mr. S. Oden Howell, Jr. Appointed to the Board of Directors
ACCESSWIRE - Thu Jun 18, 7:30AM CDT
ADDISON, TX / ACCESSWIRE / June 18, 2015 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that it has fully paid short term loans due to Brookhaven Medical Inc. This was made possible by investments from existing shareholders.
Wound Management Technologies Reports Amending and Termination of Its Shipping and Consulting Agreement with WellDyne Health
ACCESSWIRE - Thu Jun 11, 8:00AM CDT
ADDISON, TX / ACCESSWIRE / June 11, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced amending and terminating of its Shipping and Consulting Agreement dated September 19, 2013 with WellDyne Health in order to focus on its strategic shift to focus on sales internally.
Wound Management Technologies Reports Record Preliminary Financial Results for the First Quarter of 2015 and Enhanced Sales Team
ACCESSWIRE - Wed Apr 22, 9:12AM CDT
ADDISON, TX / ACCESSWIRE / April 22, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced record preliminary financial and operating results for the first quarter of 2015 and additions to its sales management team.
Wound Management Technologies, Inc. Schedules First Quarter 2015 Earnings Call for Wednesday, April 22, 2015
ACCESSWIRE - Mon Apr 20, 3:30PM CDT
ADDISON, TX / ACCESSWIRE / April 20, 2015 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced it will conduct a quarterly earnings call on Wednesday, April 22, 2015 at 3:00 p.m. CST. Robert Lutz, Jr., CEO, will discuss first quarter 2015 results and provide and update on recent activities. A question and answer session will follow the presentation. Shareholders, analysts and other interested parties may join the call by dialing 1-712-775-7031 passcode 604070847# shortly before 3:00 p.m. CST.
Wound Management Technologies Reports Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014
ACCESSWIRE - Thu Apr 09, 8:00AM CDT
ADDISON, TX / ACCESSWIRE / April 9, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced its financial and operating results for the fourth quarter and full year ended December 31, 2014.
Wound Management Technologies Exhibits at the American Academy of Orthopaedic Surgeons 2015 Annual Meeting
ACCESSWIRE - Wed Mar 18, 7:30AM CDT
ADDISON, TX / ACCESSWIRE / March 18, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM) ("Company"
, an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that its subsidiary, Wound Care Innovations ("WCI", will be an exhibitor at the American Academy of Orthopaedic Surgeons ("AAOS" Annual Meeting on March 24-28, to be held at the Venetian/Sands Expo in Las Vegas, Nevada. Wound Care Innovations will be located at booth #6729. Wound Management Technologies Expands Internationally with Inaugural Order from Mexico
ACCESSWIRE - Mon Mar 16, 7:30AM CDT
ADDISON, TX / ACCESSWIRE / March 16, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM) ("Company"
, an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that Wound Care Innovations ("WCI", a subsidiary of the Company, received its inaugural order from Mexico, where WCI is registered and signed a distribution agreement with VISECA Desarrollo Inmobiliario SA de CA ("VISECA", a healthcare distributor in Mexico. CellerateRX(R) received COFEPRIS approval from the Mexico Ministry of Health. Wound Management Technologies Reports Preliminary Financial Results For the Fourth Quarter and Year Ended December 31, 2014
ACCESSWIRE - Thu Jan 29, 7:31AM CST
ADDISON, TX / ACCESSWIRE / January 29, 2015 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced preliminary financial and operating results for the fourth quarter and year ended December 31, 2014.
Wound Management Technologies Appoints John Siedhoff to its Board of Directors
ACCESSWIRE - Tue Jan 13, 7:31AM CST
ADDISON, TX / ACCESSWIRE / January 13, 2015 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), announces that the Company has appointed John Siedhoff to its Board of Directors.
Wound Management Technologies Reports Financial Results for the Third Quarter Ended September 30, 2014
ACCESSWIRE - Thu Nov 13, 7:35AM CST
Addison, TX / ACCESSWIRE / November 13, 2014 / Wound Management Technologies, Inc. (OTC QB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced its financial and operating results for the three month period ended September 30, 2014.
Wound Management Technologies Appoints Ronald Goode and Jeffrey Lewis to the Board of Directors
Marketwired - Tue Oct 21, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), announces that the Company appointed Ronald Goode and Jeffrey Lewis to the Board of Directors.
Wound Management Technologies' CellerateRX(R) Featured in Clinical Research Session at the Symposium of Advanced Wound Care (SAWC) in Las Vegas, NV
Marketwired - Thu Oct 16, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that the product will be featured in an abstract accepted to the clinical research session at the Symposium of Advanced Wound Care (SAWC), which is being held at the Caesars Palace in Las Vegas, NV on October 16th - 18th, 2014.
Markets for Advanced Wound Management Technologies
PR Newswire - Tue Oct 14, 3:38PM CDT
This BCC Research report provides an overview of advanced wound care products, detailed market analyses and discussions of competitive environments. The study includes information about significant products, players, issues and trends and other information affecting the wound care industry.
Wound Management Technologies Appoints Dr. Blaine Farless as Medical Director of the Resorbable Orthopedic Products Subsidiary
Marketwired - Tue Oct 14, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that the Company appointed Dr. Blaine Farless as Medical Director of the Resorbable Orthopedic Products subsidiary (ROP).
Wound Management Technologies Launches Free Investor Relations App
Marketwire Canada - Tue Sep 16, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that the Company released an investor relations app for the iPhone, iPad and Android mobile devices.
Wound Management Technologies to Present at the Aegis Healthcare and Technology Conference in Las Vegas
Marketwire - Wed Sep 03, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patented-protected and FDA-cleared collagen product, CellerateRX(R), today announced that the Company's Chief Executive Officer, Robert Lutz, Jr., is scheduled to present at the Aegis Healthcare and Technology Conference on Friday, September 12, 2014 at 8:30AM PT at the Encore at the Wynn Hotel in Las Vegas, Nevada.
Wound Management Technologies Announces Its 2014 Annual Meeting of Shareholders
Marketwire - Tue Aug 26, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patented-protected and FDA-cleared collagen product, CellerateRX(R), announced that its 2014 Annual Meeting of Shareholders will be held at the Company's corporate offices located at 16633 Dallas Parkway, Suite 250 in Addison, TX on September 3, 2014 at 10AM CST.
Wound Management Technologies Launches Risk-Sharing Program to Reimburse Hospitals for Certain SSI Costs to Highlight Effectiveness of CellerateRX(r) Surgical
ACCESSWIRE - Tue Aug 19, 7:31AM CDT
Addison, TEXAS / ACCESSWIRE / August 19, 2014 / Wound Management Technologies, Inc. (OTC QB: WNDM), an emerging commercial stage company with its primary product, a patented-protected and FDA-cleared collagen product, CellerateRX(r), today announced that its Wound Care Innovations subsidiary has launched the CellerateRX(r) Surgical Assurance Program, a risk-sharing program to help hospitals and surgical centers lower the uncompensated care costs associated with readmissions due to surgical site infections (SSIs).
Wound Management Technologies Reports Financial Results for the Second Quarter Ended June 30, 2014
ACCESSWIRE - Thu Aug 14, 3:06PM CDT
Addison, TX / ACCESSWIRE / August 14, 2014 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patented-protected and FDA-cleared collagen product, CellerateRX(r), today announced its financial and operating results for the three month period ended on June 30, 2014.
